TR201909857T4 - Astım alevlenmesinin önlenmesi ve/veya tedavisi için formoterol ve beklometason dipropionat içeren bir bileşimin kullanımı. - Google Patents

Astım alevlenmesinin önlenmesi ve/veya tedavisi için formoterol ve beklometason dipropionat içeren bir bileşimin kullanımı. Download PDF

Info

Publication number
TR201909857T4
TR201909857T4 TR2019/09857T TR201909857T TR201909857T4 TR 201909857 T4 TR201909857 T4 TR 201909857T4 TR 2019/09857 T TR2019/09857 T TR 2019/09857T TR 201909857 T TR201909857 T TR 201909857T TR 201909857 T4 TR201909857 T4 TR 201909857T4
Authority
TR
Turkey
Prior art keywords
treatment
asthma
prevention
composition containing
beclomethasone dipropionate
Prior art date
Application number
TR2019/09857T
Other languages
English (en)
Inventor
Chiesi Paolo
Rondelli Ivano
Acerbi Daniela
Poli Gianluigi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201909857(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of TR201909857T4 publication Critical patent/TR201909857T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, aşağıda belirtilen maddelerin sabit bir kombinasyonunu içeren bir bileşimin kullanımı ile ilgili olup; bu maddeler arasında: a) formoterol, farmakolojik olarak kabul edilebilir tuz ya da bununla ilgili solvat veya bu türden bir tuz içeren solvat; ile b) beklometason dipropionat yer almaktadır; yukarıda belirtilen bileşim ve maddeler astım alevlenmelerinin önlenmesi ve/veya tedavisi, intermitan astım tedavisi ve/veya gerekli olduğunda semptomların giderilmesinde aynı bileşimle birlikte astıma yönelik idame tedavisi süresince kronik astımda epizodların iyileştirilmesinde kullanıma yöneliktir.
TR2019/09857T 2007-04-19 2008-04-16 Astım alevlenmesinin önlenmesi ve/veya tedavisi için formoterol ve beklometason dipropionat içeren bir bileşimin kullanımı. TR201909857T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (en) 2007-04-19 2007-04-19 Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Publications (1)

Publication Number Publication Date
TR201909857T4 true TR201909857T4 (tr) 2019-07-22

Family

ID=38458097

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09857T TR201909857T4 (tr) 2007-04-19 2008-04-16 Astım alevlenmesinin önlenmesi ve/veya tedavisi için formoterol ve beklometason dipropionat içeren bir bileşimin kullanımı.

Country Status (30)

Country Link
US (1) US20080261932A1 (tr)
EP (3) EP1982709A1 (tr)
JP (2) JP5492072B2 (tr)
KR (3) KR20100014408A (tr)
CN (1) CN101657191B (tr)
AU (1) AU2008241045C1 (tr)
BR (1) BRPI0809800A2 (tr)
CA (1) CA2684539A1 (tr)
CO (1) CO6220945A2 (tr)
CY (1) CY1117568T1 (tr)
DK (1) DK2146704T3 (tr)
EA (1) EA018589B1 (tr)
ES (2) ES2568497T3 (tr)
GE (1) GEP20145999B (tr)
HK (1) HK1137357A1 (tr)
HR (1) HRP20160588T1 (tr)
HU (1) HUE029263T2 (tr)
IL (1) IL201632A (tr)
MA (1) MA31315B1 (tr)
ME (1) ME00945B (tr)
MX (1) MX2009010851A (tr)
MY (1) MY169579A (tr)
NZ (1) NZ580526A (tr)
PL (2) PL2146704T3 (tr)
RS (1) RS54874B1 (tr)
SI (1) SI2146704T1 (tr)
TN (1) TN2009000390A1 (tr)
TR (1) TR201909857T4 (tr)
UA (1) UA100237C2 (tr)
WO (1) WO2008128685A1 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2011038872A1 (en) * 2009-10-02 2011-04-07 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
BR112014017481A8 (pt) * 2012-01-25 2021-06-15 Chiesi Farm Spa formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
MY202030A (en) * 2016-09-19 2024-03-29 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2024097413A1 (en) * 2022-11-03 2024-05-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SG48301A1 (en) 1991-12-18 1998-04-17 Astra Ab New combination
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
DK3494995T3 (da) 2002-03-01 2020-03-23 Chiesi Farm Spa Superfin formoterolformulering
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Also Published As

Publication number Publication date
TN2009000390A1 (en) 2010-12-31
MY169579A (en) 2019-04-22
DK2146704T3 (en) 2016-05-23
CA2684539A1 (en) 2008-10-30
WO2008128685A1 (en) 2008-10-30
IL201632A0 (en) 2010-05-31
EP3034073A1 (en) 2016-06-22
ES2568497T3 (es) 2016-04-29
IL201632A (en) 2016-09-29
US20080261932A1 (en) 2008-10-23
AU2008241045A1 (en) 2008-10-30
KR101668203B1 (ko) 2016-10-20
PL2146704T3 (pl) 2016-09-30
HK1137357A1 (en) 2010-07-30
AU2008241045C1 (en) 2023-06-15
EP2146704B1 (en) 2016-03-23
JP2010524873A (ja) 2010-07-22
ME00945B (me) 2012-06-20
HUE029263T2 (en) 2017-02-28
SI2146704T1 (sl) 2016-05-31
EA018589B1 (ru) 2013-09-30
KR101621676B1 (ko) 2016-05-16
JP5492072B2 (ja) 2014-05-14
AU2008241045B2 (en) 2013-06-20
CO6220945A2 (es) 2010-11-19
ES2740103T3 (es) 2020-02-05
MX2009010851A (es) 2009-11-05
GEP20145999B (en) 2014-01-10
EP1982709A1 (en) 2008-10-22
MA31315B1 (fr) 2010-04-01
CN101657191A (zh) 2010-02-24
EP3034073B1 (en) 2019-06-12
EA200901201A1 (ru) 2010-04-30
JP2014005312A (ja) 2014-01-16
CN101657191B (zh) 2014-06-11
KR20150038618A (ko) 2015-04-08
NZ580526A (en) 2012-07-27
CY1117568T1 (el) 2017-04-26
HRP20160588T1 (hr) 2016-07-01
KR20150082699A (ko) 2015-07-15
EP2146704A1 (en) 2010-01-27
BRPI0809800A2 (pt) 2014-10-07
KR20100014408A (ko) 2010-02-10
PL3034073T3 (pl) 2019-11-29
RS54874B1 (sr) 2016-10-31
UA100237C2 (uk) 2012-12-10

Similar Documents

Publication Publication Date Title
TR201909857T4 (tr) Astım alevlenmesinin önlenmesi ve/veya tedavisi için formoterol ve beklometason dipropionat içeren bir bileşimin kullanımı.
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BR112012018022A2 (pt) inibição de sinalização axl em terapia antimetastática.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
ATE413816T1 (de) Synergie von gos und polyfruktose
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
UY31017A1 (es) Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
WO2006036770A3 (en) Combination therapy for the treatment of obesity
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2008125116A3 (en) Upar inhibition
MY146091A (en) Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
EA201171035A1 (ru) Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2013152193A3 (en) Methods of treating proliferative disorders with malate or derivatives thereof
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств